Seoul, Korea, Aug. 2, 2026 /PRNewswire/ -- Mezzion Pharma Co., Ltd. today announced positive results from a new in vivo study of udenafil, a novel phosphodiesterase type 5 (PDE5) inhibitor, in autosomal dominant polycystic kidney disease (ADPKD). In a preclinical ADPKD model, udenafil...
Hence then, the article about mezzion reports positive in vivo results for udenafil in adpkd was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Mezzion Reports Positive In Vivo Results for Udenafil in ADPKD )
Also on site :
- Burnham pledges more cost of living support as chancellor says public being ‘taken for a ride’ on food and petrol prices
- ‘Hacks’ Stars Hannah Einbinder and Paul W. Downs on the Legacy of ‘Hacks’ and Which Character Needs a Spinoff First
- Crumbl CEO says he shuts shop on Sundays and prioritizes game nights with his 7 kids in pursuit of balance: Life can’t be ‘just go, go, go’